Search

Displaying results 3761 - 3770 of 9132 in total
  1. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease … Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its

  2. Drug

    Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)

    go.drugbank.com/drugs/DB15863
    Experimental

    As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538). … The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells[A219758].

  3. Drug

    3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole

    go.drugbank.com/drugs/DB08727
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. 3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is known to target genome … 3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is a solid. This compound belongs to the phenol ethers.

  4. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    used a research tool. … A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

  5. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been … It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

    Synonyms: Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-
  6. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site. … It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin.

  7. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.

  8. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  9. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

    Synonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
  10. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    INCB13739 is developed as a new treatment for type 2 diabetes. … It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes